Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neutrophil extracellular trap DNA is the decondensed chromatin released from activated neutrophils as part of NETs, which are web-like extracellular structures composed primarily of DNA, histones, and antimicrobial proteins. These structures trap and kill pathogens in the extracellular space and contribute to immune defense but are also implicated in inflammatory diseases, autoimmunity, thrombosis, and cancer. The DNA backbone of NETs is directly antimicrobial and acts as a scaffold for associated proteins. Excess NETs or impaired clearance can drive pathology through inflammation, tissue damage, vessel occlusion, and the induction of autoantibodies[1][3][5][7][9].
Degradation of extracellular DNA (by DNase) to dissolve NETs and reduce their pathogenic effects; Inhibition of chromatin decondensation and histone modification (by PAD4 inhibitors); Suppression of NET formation (colchicine, chloroquine)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neutrophil extracellular trap DNA (NET DNA).